Stoke Therapeutics Stock News

Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

After losing some value lately, a hammer chart pattern has been formed for Stoke Therapeutics, Inc. (STOK), indicating that the stock has found support. This, combined with an upward trend in earnings

Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-sq

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit

Stoke Therapeutics (NASDAQ: STOK ) reported its Q4 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Stoke Therapeutics missed estimated earnings by 6.45%, reporting an EPS of … Full story available on Benzinga.com

Stoke Therapeutics press release (STOK): Q4 GAAP EPS of -$0.66 misses by $0.04.As of December 31, 2021, Company had $220.4 million in cash, cash equivalents, marketable securities,…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET. A live webcast will be available on the Investors & News section of Stoke’s website at https://investor.st

The consensus price target hints at a 192.2% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in

Stoke Therapeutics <> is trading higher after Jefferies launched its coverage with a Buy recommendation noting the prospects of its proprietary ribonucleic acid ((RNA))

Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) and Stoke Therapeutics Inc (NASDAQ: STOK ) will team up on the treatments in rare genetic neurodevelopmental diseases of the CNS. The recently discovered SYNGAP1 syndrome will be first, followed by Rett syndrome (MECP2) and an undisclosed target the biotechs say is of mutual interest. “Combining Stoke’s capabilities with Acadia’s extensive expertise in … Full story available on Benzinga.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares traded up 4.1% on Wednesday . The company traded as high as $18.92 and last traded at $18.85. 3,629 shares changed hands during trading, a decline of 98% from the average session volume of 162,092 shares. The stock had previously closed at $18.11. A number of equities research analysts have […]

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) rose 4.1% during mid-day trading on Wednesday . The stock traded as high as $18.92 and last traded at $18.85. Approximately 3,629 shares traded hands during trading, a decline of 98% from the average daily volume of 162,092 shares. The stock had previously closed at $18.11. STOK has been []

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $18.12 and last traded at $18.21, with a volume of 4279 shares. The stock had previously closed at $19.73. Several research firms have recently issued reports on STOK. Cantor Fitzgerald reiterated an overweight []